http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
-
Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results
-
Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering
-
Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors
-
Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-2
-
Cotinga Pharmaceuticals Doses First Patient With Combination Therapy in Phase 1b/2a Trial of COTI-2
-
Cotinga Pharmaceuticals Enrolls Two Patients for Combination Therapy in Phase 1b/2a Trial of COTI-2
-
Cotinga Pharmaceuticals Reports Fiscal 2019 Second Quarter Financial and Operating Results
-
Cotinga Pharmaceuticals Announces Research Partnership with St. Vincent’s University Hospital to Evaluate COTI-2
-
Cotinga Pharmaceuticals Reports Fiscal 2019 First Quarter Financial and Operating Results
-
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at 11th International Symposium on Translational Research in Oncology
-
Cotinga Pharmaceuticals Reports Fiscal 2018 Fourth Quarter and Full Year Financial and Operating Results
-
Cotinga Pharmaceuticals Announces Management and Board Changes
-
Cotinga Pharmaceuticals Announces FDA Clearance of Significant Protocol Changes for COTI-2 Clinical Program
-
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the 2018 American Society of Clinical Oncology Annual Meeting
-
Cotinga Pharmaceuticals Closes $2.0M Private Placement
-
Cotinga Pharmaceuticals Reports Fiscal 2018 Third Quarter Financial and Operating Results
-
Cotinga Pharmaceuticals Announces Presentation on COTI-2 at the American Association for Cancer Research (AACR) Annual Meeting 2018
-
Cotinga Pharmaceuticals Provides Update on COTI-2 Clinical Programs
-
Cotinga Pharmaceuticals to Present at 30th Annual ROTH Conference
-
Cotinga Pharmaceuticals Announces Publication of Positive Data from Preclinical Study of COTI-2 in PLOS ONE
-
Critical Outcome Technologies Changes Name to Cotinga Pharmaceuticals
-
Critical Outcome Technologies Reports Fiscal 2018 Second Quarter Financial and Operating Results
-
Critical Outcome Technologies Awards Stock Options
-
Critical Outcome Technologies Provides Scientific and Business Update at Annual General Meeting and Announces Approval of Name Change
-
Critical Outcome Technologies Announces Pharmacodynamic Data and Positive Signals of Efficacy from Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
-
Critical Outcome Technologies Annual and Special Meeting of Shareholders Rescheduled
-
Critical Outcome Technologies Announces Pharmacokinetic Data From Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
-
Critical Outcome Technologies Closes Second Tranche of $2 Million Private Placement
-
Critical Outcome Technologies Announces First Patient Dosed in Phase 1 Trial of COTI-2 in Head and Neck Squamous Cell Carcinoma
-
Critical Outcome Technologies Reports Fiscal 2018 First Quarter Financial and Operating Results
-
Critical Outcome Technologies Closes $1.5 Million Private Placement
-
Critical Outcome Technologies Announces CEO to Co-chair Global Genes Rare Partnering & Investor Forum
-
Critical Outcome Technologies to Present at Rodman & Renshaw 19th Annual Global Investment Conference
-
Critical Outcome Technologies Announces Fourth Quarter and Full Year 2017 Financial Results
-
Critical Outcome Technologies Completes Phase 1 Dose Escalation Portion of COTI-2 Trial in Gynecological Malignancies
-
Critical Outcome Technologies Addresses Recent Trading Activity
-
Critical Outcome Technologies Announces Share Consolidation
-
Cott Corp. (COT) Announces CHEP as New U.S. Pallet Provider
-
CHEP Signs New Agreement with Cott to Become Its Pallet Provider in the U.S.
-
Critical Outcome Technologies Appoints Experienced Biotech Leader as Chief Scientific Officer
-
Critical Outcome Technologies Announces CEO to Moderate Rare Diseases Panel at BIO-Europe
-
Critical Outcome Technologies Reports Third Quarter Financial and Operating Results for Fiscal Year 2017
-
Critical Outcome Technologies Announces Departure of Chief Scientific Officer
-
Critical Outcome Technologies to Be a Panelist and Presenter at Cantech Investment Conference in Toronto
-
Critical Outcome Advances to Fourth Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers
-
Critical Outcome Technologies Awards Stock Options
-
Critical Outcome Technologies Reports Second Quarter Financial and Operating Results for Fiscal 2017
-
Critical Outcome Technologies Appoints Alison Silva as Chief Executive Officer
-
Critical Outcome Technologies Awards Stock Options

